Your browser doesn't support javascript.
loading
Endoscopic band ligation is safe despite low platelet count and high INR.
Pfisterer, Nikolaus; Schwarz, Michael; Jachs, Mathias; Putre, Florian; Ritt, Lukas; Mandorfer, Mattias; Madl, Christian; Trauner, Michael; Reiberger, Thomas.
Afiliación
  • Pfisterer N; Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • Schwarz M; Vienna Hepatic Hemodynamic Lab, Medical University of Vienna, Vienna, Austria.
  • Jachs M; 4. Medizinische Abteilung für Gastroenterologie und Hepatologie, Klinik Landstrasse, Vienna, Austria.
  • Putre F; Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • Ritt L; Vienna Hepatic Hemodynamic Lab, Medical University of Vienna, Vienna, Austria.
  • Mandorfer M; 4. Medizinische Abteilung für Gastroenterologie und Hepatologie, Klinik Ottakring, Vienna, Austria.
  • Madl C; Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • Trauner M; Vienna Hepatic Hemodynamic Lab, Medical University of Vienna, Vienna, Austria.
  • Reiberger T; Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Hepatol Int ; 17(5): 1205-1214, 2023 Oct.
Article en En | MEDLINE | ID: mdl-37024710
BACKGROUND: Prophylactic endoscopic band ligation (EBL) is used to prevent variceal bleeding in patients with liver cirrhosis. The association of thrombocytopenia, high INR (international normalized ratio) and liver dysfunction with the risk of procedure-related bleeding (PRB) remains debated and recommendations are controversial. METHODS: We analyzed real-life data of cirrhotic patients undergoing elective EBL at two large Viennese centers between Q1/2000-Q1/2018. PRB was defined as bleeding occurring within 30 days after EBL. RESULTS: We included 617 patients undergoing a total of 1178 prophylactic EBL procedures (median 2 per patient). Sixteen (2.6%) of 617 patients experienced PRB after a median of 12.5 (IQR 17.3) days with no difference in characteristics and laboratory values between the two groups. The proportion of patients with platelets (PLT) < 50 G/L or INR ≥ 1.5 was similar in patients with vs. without PRB. A higher MELD showed a non-significant association with EBL-related bleeding risk (odds ratio, OR 1.07; 95% confidence interval 95% CI 1.00-1.16, p = 0.058). While serum bilirubin was a significant predictor for PRB (OR: 1.10; 95% CI 1.03-1.18), the presence of large varices (OR 0.85 vs. small varices; 95% CI 0.20-3.84), INR (OR 0.50; 95% CI 0.10-3.14), PLT (OR 1.00; 95% CI 1.00-1.01) and the use of non-selective betablockers (OR 1.20; CI 95% 0.38-3.76) were not associated with PRB. CONCLUSION: EBL is safe and procedure-related bleedings are rare (2.6%) including in patients with thrombocytopenia < 50 G/L or high INR ≥ 1.5. Only high MELD, and especially high bilirubin seem to be linked to an increased risk of EBL-related bleeding.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trombocitopenia / Várices / Várices Esofágicas y Gástricas Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Hepatol Int Año: 2023 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trombocitopenia / Várices / Várices Esofágicas y Gástricas Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Hepatol Int Año: 2023 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Estados Unidos